Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Common Equity (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Common Equity for 9 consecutive years, with $614.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 8.97% to $614.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $614.7 million through Dec 2025, down 8.97% year-over-year, with the annual reading at $614.7 million for FY2025, 8.97% down from the prior year.
  • Common Equity hit $614.7 million in Q4 2025 for Protagonist Therapeutics, down from $645.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $689.1 million in Q1 2025 to a low of $215.6 million in Q4 2022.
  • Historically, Common Equity has averaged $417.5 million across 5 years, with a median of $333.2 million in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 313.84% in 2021 and later fell 28.37% in 2023.
  • Year by year, Common Equity stood at $300.0 million in 2021, then fell by 28.14% to $215.6 million in 2022, then surged by 56.15% to $336.7 million in 2023, then soared by 100.58% to $675.3 million in 2024, then fell by 8.97% to $614.7 million in 2025.
  • Business Quant data shows Common Equity for PTGX at $614.7 million in Q4 2025, $645.4 million in Q3 2025, and $668.0 million in Q2 2025.